Paliperidone Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva, is a long‑acting atypical antipsychotic presented as an injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Paliperidone Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone palmitate is a long‑acting formulation that acts on dopamine and serotonin pathways to manage chronic psychotic disorders.

- Schizophrenia: Reduces the frequency of psychotic relapses and stabilises mood in adult patients. - Schizoaffective disorder: Helps maintain symptom control when oral therapy is insufficient. - Maintenance therapy for schizophrenia: Provides consistent plasma levels to minimise breakthrough symptoms between oral dosing intervals.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Injection site pain or erythema - Headache - Drowsiness or somnolence - Weight gain - Restlessness (akathisia) - Dry mouth

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes - Seizures - Elevated prolactin with associated endocrine effects

When prescribing Paliperidone Teva, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: Check blood glucose and lipid profiles regularly. - Movement disorders: Observe for signs of tardive dyskinesia or akathisia. - Pregnancy and lactation: Use only if the potential benefit justifies the risk. - Elderly patients: Start at the lowest recommended dose and monitor closely for sedation. - Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with other medicines that affect its metabolism or cardiac conduction.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase paliperidone exposure. - QT‑prolonging agents (e.g., quinidine, sotalol): Heighten risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, opioids): May enhance sedation. - Antihypertensives: May potentiate orthostatic hypotension. - Antidiabetic drugs: May require dose adjustment if hyperglycaemia develops.